Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New software to help researchers study specific information about proteins

What if scientists could create more effective drugs to treat cancers and other diseases by better targeting specific sites on proteins in the body?

11 Dec 2019

Experimental Alzheimer’s drugs show promise

Researchers from Salk have found that two experimental drugs named CMS121 and J147 may improve memory functions and reduce the progression of memory decline and brain degeneration in mice models of Alzheimer’s disease (AD). The researchers published their work in the latest issue of the journal eLife. The study was titled, “Elevating acetyl-CoA levels reduces aspects of brain aging.”

11 Dec 2019

Stilla Technologies announces key leadership hires

Stilla Technologies, the provider of pioneering digital PCR solutions for high-precision genetic analysis, today announced three key hires: Khaled Bahi joins as CFO, with Jerome Leclercq named Senior Vice President for Commercial Operations Europe & Asia and Quang Tran named Quality & Regulatory Affairs Director.

11 Dec 2019

Experts say cancer research is making more progress that people think

The focus on a “cure for cancer” is masking progress made in extending lifespan and making cancer manageable in the long-term.

9 Dec 2019

Intellegens and Optibrium announce success in the Open Source Malaria global initiative

Intellegens, an artificial intelligence start-up, and, Optibrium, leading providers of software and services for drug discovery, today announced joint success in the Open Source Malaria global initiative aimed at identifying the best predictive models for antimalarial compounds.

6 Dec 2019

Biosero and RORZE Lifescience collaborate to commercialize Green Button Go Automation Scheduling Software in Asia

Biosero, Inc. announced a new partnership wherein RORZE Lifescience, Inc., a subsidiary of Rorze, Inc., will commercialize Biosero’s Green Button Go Automation Scheduling Software in Asia.

From Biosero Inc. 6 Dec 2019

Coriell scientist awarded grant to explore epigenetic drivers of breast cancer

Shoghag Panjarian, PhD, a research scientist at the Coriell Institute for Medical Research, has been awarded a grant from the W. W. Smith Charitable Trust to support her search for epigenetic factors that contribute to the development and growth of breast cancer.

5 Dec 2019

Pharma’s take on the Pelosi drug-pricing bill: Fair warning or fearmongering?

House Speaker Nancy Pelosi's flagship proposal to curb prescription drug prices, the "Lower Drug Costs Now Act" - H.R. 3 - could come up for a vote in the chamber this month.

5 Dec 2019

Georgia State professor selected as National Academy of Inventors Fellow

Jenny Yang, a Regents' Professor of chemistry at Georgia State University and the associate director of the Center for Diagnostics and Therapeutics, has been selected as a National Academy of Inventors (NAI) Fellow, the academy board announced on Tuesday.

5 Dec 2019

ADDF announces new awards through its Diagnostics Accelerator initiative

The Alzheimer's Drug Discovery Foundation announced six new investments totaling $6 million through its Diagnostics Accelerator initiative.

4 Dec 2019

Newly developed cell models can open up new avenues for ocular drug discovery

Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery. The new cell models are continuously growing retinal pigment epithelial cells, which have many benefits over the models currently used by researchers and pharmaceutical companies. The models were developed by Professor Arto Urtti's Ocular Drug Delivery group at the University of Eastern Finland.

4 Dec 2019

LUNAC-led drug discovery project receives funding under Innovate UK’s Biomedical Catalyst program

LUNAC Therapeutics, a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, today announced that, along with the Medicines Discovery Catapult and the University of Leeds, it has been awarded £3.14M funding under Innovate UK’s Biomedical Catalyst program.

4 Dec 2019

Metrion and LifeArc extend neuroscience-focused ion channel drug discovery collaboration

Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced an extension of their neuroscience-focused ion channel drug discovery collaboration, following the success of the initial twelve-month agreement.

From Metrion Biosciences Limited 4 Dec 2019

Scientist earns prestigious award for research into cell suicide

Apoptosis is a form of “cell suicide”, where a cell self-terminates, ideally as planned or programmed, enabling multi-cellular organisms to continue to live, develop and thrive.

4 Dec 2019

IONTAS, Adaptate Biotherapeutics join forces to generate and optimize antibodies for novel cancer targets

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.

From FairJourney Biologics 4 Dec 2019

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

The growing trend of implementing immunotherapy into oncology has resulted in various new therapeutic cancer treatments utilizing antibodies.

From Sartorius 3 Dec 2019

Consortium launches ambitious project to transform the treatment of pain

In an effort to address the critical public health need for new, safer and more effective medicines to treat pain, a consortium based at the Laboratory of Systems Pharmacology at Harvard Medical School has launched an ambitious project titled STOP PAIN (Safe Therapeutic Options for Pain and Inflammation).

2 Dec 2019

One Nucleus reveals finalists of annual BioNewsRound Award

One Nucleus reveals the finalists of its annual BioNewsRound Award, recognizing life science companies that have announced exciting developments for patients and the sector. The finalists will present at Genesis 2019 where the winner will be announced.

29 Nov 2019

ICR scientists carry out first comprehensive assessment of chemical probe resources

A new report urges biomedical researchers to use online web resources very carefully, taking into account their complementary benefits and weaknesses, when selecting small-molecule chemical probes to help answer their research questions.

28 Nov 2019

Oligomerix and Feinstein Institutes publish preclinical data of Alzheimer's disease treatment

Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.

26 Nov 2019